Want to see JP:4534 full AI Analyst Report?

Mochida Pharmaceutical Co., Ltd. (4534) Price & Analysis

1 Followers

4534 Stock Chart & Stats

¥3615.00

-¥40.00(-1.17%)

At close: Jan 08 4:00 PM EST

¥3615.00

-¥40.00(-1.17%)

Day’s Range― - ―

52-Week Range¥2,929.00 - ¥3,965.00

Previous CloseN/A

Volume18.00K

Average Volume (3M)34.37K

Market Cap

¥105.83B

Enterprise Value¥101.93K

Total Cash (Recent Filing)¥31.06B

Total Debt (Recent Filing)¥10.00B

Price to Earnings (P/E)13.9

Beta0.61

Next Earnings

Aug 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.34%

Share Statistics

EPS (TTM)222.94

Shares Outstanding36,390,000

10 Day Avg. Volume38,620

30 Day Avg. Volume34,366

Financial Highlights & Ratios

PEG Ratio0.40

Price to Book (P/B)0.87

Price to Sales (P/S)1.05

P/FCF Ratio-12.21

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)208.3

Revenue Forecast (FY)¥110.00B

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low historical leverage and a large equity base give Mochida financial flexibility to fund R&D, support manufacturing or licensing efforts, and absorb cyclical shocks. This conservatism reduces refinancing risk and preserves optionality for strategic investments over the medium term.

Rebounding Revenue And ProfitSustained top-line growth and rising net income through 2026 indicate improving product traction and operational recovery. This strengthens the company's ability to reinvest in pipelines, maintain commercial efforts, and support steady earnings generation over the next several quarters.

Specialized Product Focus And Sales NetworkA focused portfolio in specialty therapy areas plus an established MR-driven domestic sales and distribution capability supports durable prescription demand and effective commercialization of in-licensed products, preserving market position and steady revenue streams over time.

Bears Say

Volatile Cash GenerationLarge swings and intermittent negative OCF/FCF point to working-capital timing or collection issues that undermine the reliability of reported profits converting to cash. This hampers the company's ability to self-fund capex, dividends, or acquisitions without external financing.

Margin And Earnings InconsistencyMaterial margin volatility implies sensitivity to product mix, pricing or reimbursement dynamics. That inconsistency reduces predictability of earnings and complicates multi-quarter planning for R&D, marketing spend, and dividend policy, raising execution risk.

Recent Increase In DebtThe rise in reported debt in 2026, while modest versus equity, increases interest and refinancing exposure. Combined with volatile cash flows, higher debt levels could constrain financial flexibility and raise funding costs when executing strategic initiatives.

Mochida Pharmaceutical Co., Ltd. News

Mochida Advances Share Buyback Under ¥2 Billion Authorization

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) has provided an update. Mochida Pharmaceutical has disclosed the latest progress...

17d ago

Mochida Pharmaceutical Reports Initial Progress on Share Buyback Program

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) has issued an update. Mochida Pharmaceutical has disclosed the latest progress...

2M ago

Mochida Pharmaceutical Reshapes Executive Lineup to Sharpen Business Focus

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) has provided an announcement. Mochida Pharmaceutical announced board-level leadership changes effective...

2M ago

Mochida Pharmaceutical Lifts Profits and Raises Dividend Outlook for FY2027

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) has issued an announcement. Mochida Pharmaceutical reported solid growth for the...

2M ago

Mochida Pharmaceutical Sets Terms for Secondary Share Offering and Over-Allotment

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) just unveiled an announcement. Mochida Pharmaceutical has set the terms for...

3M ago

Mochida Pharma Clears Audit Review as Profits Rise Ahead of Secondary Share Offering

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) has provided an announcement. Mochida Pharmaceutical said an independent auditor has...

4M ago

Mochida Pharmaceutical Unveils Up to ¥2 Billion Share Buyback Plan

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) has provided an update. Mochida Pharmaceutical Co., Ltd. has approved a...

4M ago

Mochida Pharmaceutical Plans Secondary Share Offering to Boost Liquidity

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) has shared an update. Mochida Pharmaceutical will conduct a secondary offering...

4M ago

Mochida to Acquire Full Rights to URECE Gout Drug from Fuji Yakuhin

Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) has issued an announcement. Mochida Pharmaceutical has agreed to take over...

4M ago

Mochida Pharmaceutical Lifts Nine-Month Earnings and Raises Full-Year Profit Forecast

An announcement from Mochida Pharmaceutical Co., Ltd. ( ($JP:4534) ) is now available. For the nine months ended...

5M ago

4534 FAQ

What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Mochida Pharmaceutical Co., Ltd. lowest stock price was ¥2929.00 and its highest was ¥3965.00 in the past 12 months.

What is Mochida Pharmaceutical Co., Ltd.’s market cap?

Mochida Pharmaceutical Co., Ltd.’s market cap is ¥105.83B.

When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 03, 2026 which is in 16 days.

How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?

Mochida Pharmaceutical Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥44.05 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Mochida Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Mochida Pharmaceutical Co., Ltd. pay dividends?

Mochida Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥42.5 which represents an annual dividend yield of 2.34%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here

What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?

Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?

Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.

What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Mochida Pharmaceutical Co., Ltd. reported an EPS of ¥44.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.399%.

Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4534

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mochida Pharmaceutical Co., Ltd.

Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.